Brookstone Capital Management acquired a new position in Harrow, Inc. (NASDAQ:HROW - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 8,188 shares of the company's stock, valued at approximately $275,000.
Other large investors have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company's stock worth $57,000 after purchasing an additional 227 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Harrow by 5.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,865 shares of the company's stock valued at $248,000 after acquiring an additional 567 shares during the last quarter. Quest Partners LLC acquired a new position in Harrow during the third quarter valued at $29,000. Hills Bank & Trust Co purchased a new stake in Harrow in the 3rd quarter worth approximately $107,000. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Harrow by 64.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 6,825 shares of the company's stock valued at $307,000 after acquiring an additional 2,668 shares during the period. Institutional investors own 72.76% of the company's stock.
Harrow Trading Up 1.2 %
Shares of Harrow stock traded up $0.39 during trading hours on Friday, reaching $33.85. 277,666 shares of the company were exchanged, compared to its average volume of 277,883. The stock's fifty day moving average is $38.15 and its 200 day moving average is $38.82. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a 1 year low of $9.13 and a 1 year high of $59.23.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on HROW. Lake Street Capital raised their price objective on Harrow from $45.00 to $55.00 and gave the company a "buy" rating in a report on Friday, October 4th. Craig Hallum raised their price objective on Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a research report on Friday, October 4th. Finally, B. Riley decreased their target price on shares of Harrow from $73.00 to $69.00 and set a "buy" rating on the stock in a research report on Wednesday, December 4th.
Read Our Latest Analysis on HROW
Harrow Profile
(
Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Further Reading
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
